Gibson Dunn has advised Avere Therapeutics. Cooley has advised the placement agents. Avere Therapeutics, Inc. (“Avere”), a privately-held biotechnology company, has announced a $500 million private...
Avere Therapeutics Secures $500 Million in Private Placement for Development of Once-Weekly Oral IL-23 Therapy
LB Pharmaceuticals Completes $150 Million Private Placement of Common Stock and Pre-Funded Warrants
Cooley LLP has advised LB Pharmaceuticals Inc. Mintz has advised Leerink Partners and Piper Sandler as placement agents. LB Pharmaceuticals Inc. (Nasdaq: LBRX) has announced the...
Synlogic and Caldera Therapeutics Announce Merger and $278 Million Private Placement
Mintz has advised Synlogic Inc. Fenwick & West has advised Caldera Therapeutics. Cooley has advised the placement agents to Caldera Therapeutics. Synlogic, Inc. (OTC: SYBX) and...
Alvotech Announces $152 Million Public Offering and Concurrent Private Placement
Paul Hastings LLP has advised BofA Securities, Jefferies, and Evercore ISI. Cooley LLP has advised Alvotech. Alvotech has launched an aggregate public offering and concurrent private...
Odyssey Therapeutics Announces $304 Million Upsized IPO and Private Placement
Covington and Wilson Sonsini have advised Odyssey Therapeutics. Cooley has advised the underwriters. Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases,...
Galecto Closes $316 Million Public Offering of Common Stock
Gibson Dunn has advised Galecto, Inc. Cooley LLP has advised the underwriters. Goodwin Procter LLP acted as intellectual property counsel for Galecto, Inc. Galecto, Inc. (Nasdaq:...
SERB Pharmaceuticals Acquires Y-mAbs Therapeutics in $412 Million All-Cash Transaction
Cooley has advised Y-mAbs Therapeutics, while Wilson Sonsini Goodrich & Rosati has advised Centerview Partners, financial advisor to Y-mAbs Therapeutics. SERB Pharmaceuticals, a global specialty pharmaceutical...
LB Pharmaceuticals Launches $285 Million Initial Public Offering
Cooley has advised LB Pharmaceuticals on the offering, and Mintz has advised the underwriters. LB Pharmaceuticals Inc has announced the pricing of its upsized initial public...
BioAge Labs’ $238 Million Upsized Initial Public Offering
Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
Astria Therapeutics’ $125 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr advised Astria Therapeutics, Inc., and Cooley advised the underwriters. Astria Therapeutics, Inc. (Astria) (Nasdaq: ATXS) announced it completed its underwritten registered...
Turnstone Biologics Corp.’s $80 Million Initial Public Offering
Cooley represented Turnstone, and Latham & Watkins represented the underwriters in the IPO. Turnstone Biologics Corp. (Nasdaq: TSBX) announced the pricing of its upsized initial public...
Argenx’s $1.27 Billion Follow-On Offering
Goodwin and Freshfields advised argenx, while Cooley advised the representatives of the several underwriters on the offering. argenx SE closed its $1.27 billion follow-on offering. On July 19,...